Acamprosate 333 mg Gastro-resistant Tablets. Each gastro-resistant tablet contains Acamprosate Calcium 333 mg as the active ingredient. For the full list of excipients, see section 6.1. Gastro-resistant tablet. White, round, biconvex coated tablet plain on both sides. Acamprosate is indicated as therapy to maintain abstinence in alcohol-dependent patients. It should be combined with counselling. Posology Adults within the age range 18-65 years - 2 tablets three times daily with meals (2 tablets in the morning, noon and night) in subjects weighing 60 kg or more. - In subjects weighing less than 60kg, 4 tablets are divided into three daily doses with meals (2 tablets in the morning, 1 at noon and 1 at night). Paediatric population and older people Acamprosate should not be administered to children, adolescents and the elderly. Duration of treatment The recommended treatment period is one year. Treatment with Acamprosate Calcium 333 Mg should be initiated as soon as possible after the withdrawal period and should be maintained if Acamprosate Calcium 333 Mg does not prevent the harmful effects of continuous alcohol abuse. Continued alcohol abuse negates the therapeutic benefit; therefore Acamprosate Calcium 333 Mg treatment should only be initiated after weaning therapy, once the patient is abstinent from alcohol.
